CDMO — Avid Bioservices Cashflow Statement
0.000.00%
- $801.14m
- $929.71m
- $139.91m
- 47
- 18
- 53
- 33
Annual cashflow statement for Avid Bioservices, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K/A | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.5 | 11.2 | 128 | 0.259 | -141 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 2.51 | 4.77 | 8.79 | 12.2 | 13.3 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 10.7 | 11.7 | -16.4 | -33.7 | 13.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 5.83 | 31.2 | 9.46 | -12.7 | 11 |
| Capital Expenditures | -3.81 | -9.86 | -56.4 | -77.8 | -31.8 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0 | — | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -3.81 | -9.86 | -56.4 | -77.8 | -31.8 |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.1 | 112 | 3.2 | 2.9 | 20.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.11 | 134 | -43.7 | -87.6 | -0.786 |